Sun Underlines 'Competitive Profile' Of Psoriasis Asset In Crowded Market
India's Sun Pharma, the world's fifth largest specialty generic company, emphasized the "very competitive profile" of its late-stage psoriasis asset, tildrakizumab, at its Q2 earnings, but will that hold in a market that is expected to become increasingly saturated?
You may also be interested in...
Sun Pharmaceutical, the world’s fifth-largest specialty generic company, has reported positive results from two pivotal Phase III clinical trials for its psoriasis candidate tildrakizumab, showing that the targeted biologic therapy delivers “significantly improved” skin clearance. While it will face rising competition, some analysts are predicting strong sales
Despite being able to show superiority over market leader AbbVie's Humira (adalimumab), Johnson & Johnson will need to invest heavily in order to drive uptake for guselkumab if the drug is successfully approved next year for the treatment of psoriasis.
Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.